← Back to Search

Other

Geranylgeraniol Treatment for Low Sex Drive

N/A
Waitlist Available
Research Sponsored by Applied Science & Performance Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 4 and 8
Awards & highlights

Study Summary

The purpose of this study will be to examine the effectiveness of Geranylgeraniol supplementation on sexual health function in males and females following an 8-week dose escalation intervention. The study will be carried out in a randomized, double-blind, placebo-controlled, parallel manner. Participants will be stratified into quartiles based on their scores on the Derogatis Interview for Sexual Functioning during screening and prior to baseline testing. Participants from each quartile will be randomly divided by into treatment or placebo conditions. Following randomization, participants will be baseline assessed on their sexual health function using a variety of questionnaires, body composition using a whole body Dual Energy X-Ray Absorptiometry scan, blood chemistry panel, and grip strength using a hand-held dynamometer. Following baseline testing, participants will undergo 8 weeks of supplementation of their respective supplement condition. Participants will be instructed to consume two servings a day (150mg total per day) from weeks 1-4. Subject will return to the study site after 4 weeks to reassess the above-mentioned parameters. Participants will then undergo a dose escalation and be instructed to consume two servings a day (300mg total per day) from week 5-8. Sexual health questionnaires and assessments of body composition, blood chemistry, and grip strength will be conducted following the week 8 to conclude the study.

Eligible Conditions
  • Low Sex Drive
  • Sexual Wellness

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 4 and 8
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 4 and 8 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Changes in Aging Male Symptoms
Changes in Androgen Deficiency in Aging Males Scale
Changes in Erectile Function
+6 more
Secondary outcome measures
Changes in Alanine Transaminase levels
Changes in Albumin levels
Changes in Albumin to Globulin ratio
+54 more
Other outcome measures
Adverse Effects
Resting Diastolic Blood Pressure
Resting Systolic Blood Pressure

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Geranylgeraniol TreatmentExperimental Treatment1 Intervention
From weeks 1-4, participants will consume 150mg daily of a Geranylgeraniol (GG). For weeks 5-8, the dose will be escalated as participants will consume 300mg daily of GG.
Group II: PlaceboPlacebo Group1 Intervention
From weeks 1-4, participants will consume 150mg daily of a visually identical placebo. For weeks 5-8, the dose will be escalated as participants will consume 300mg daily of placebo supplementation.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
GG sourced from Annatto
2022
N/A
~90

Find a Location

Who is running the clinical trial?

Applied Science & Performance InstituteLead Sponsor
11 Previous Clinical Trials
596 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~26 spots leftby Apr 2025